OF
SYRE icon

Optimize Financial’s Spyre Therapeutics SYRE Stock Holding History

Optimize Financial’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,331
Closed -$830K – 445
2025
Q4 		$830K Buy
25,331
+364
+1% +$9.51K 0.42% 55
2025
Q3 		$418K Buy
+24,967
New +$407K 0.22% 192

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Optimize Financial's SYRE Position: Q1 2026 in Review

Optimize Financial sold out of Spyre Therapeutics (SYRE) in Q1 2026, closing a stake of 25,331 shares — an estimated $830K sold.

Optimize Financial first reported a position in SYRE in Q3 2025 and held it in 2 quarters. The position peaked at $830K in Q4 2025. 198 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Optimize Financial reported no remaining Spyre Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Optimize Financial sold 25,331 Spyre Therapeutics shares in Q1 2026, an estimated $830K.
  • Optimize Financial first reported a position in Spyre Therapeutics in Q3 2025 and held it in 2 quarters.
  • Optimize Financial's Spyre Therapeutics position peaked at $830K in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Optimize Financial's 13F filing for Q1 2026, filed 12 May 2026.